Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing admin@sinochem-nanjing.com 3389378665@qq.com
Follow us:

Mitiglinide Calcium Dihydrate

    • Product Name Mitiglinide Calcium Dihydrate
    • Alias Glufast
    • Mininmum Order 1 g
    • Factory Site Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing
    • Price Inquiry admin@sinochem-nanjing.com
    • Manufacturer Sinochem Nanjing Corporation
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    358089

    Chemical Name Mitiglinide Calcium Dihydrate
    Molecular Formula C23H27NO5S2·Ca·2H2O
    Molecular Weight 557.7 g/mol
    Appearance White to off-white powder
    Cas Number 207844-01-7
    Solubility Slightly soluble in water, soluble in methanol
    Storage Temperature 2-8°C
    Pharmacological Class Meglitinide analog, antidiabetic agent
    Mechanism Of Action Stimulates insulin secretion from pancreatic β-cells
    Indication Type 2 diabetes mellitus
    Route Of Administration Oral
    Brand Names Glufast (Japan)
    Synonyms KAD-1229 calcium dihydrate
    Melting Point Around 205°C (decomposes)
    Expiry Conditions Protect from light and moisture

    As an accredited Mitiglinide Calcium Dihydrate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Mitiglinide Calcium Dihydrate is packaged in a 25g amber glass bottle with tamper-evident seal, labeled with product and safety information.
    Shipping Mitiglinide Calcium Dihydrate is shipped in sealed, moisture-resistant containers under ambient conditions. Packaging complies with chemical safety regulations to prevent contamination and ensure stability. Each shipment includes proper labeling, safety data sheets, and documentation. Temperature and handling instructions are observed as required. Expedited shipping is available upon request.
    Storage Mitiglinide Calcium Dihydrate should be stored in a tightly closed container, protected from light and moisture. Keep the storage temperature at 2–8°C (refrigerated conditions). Ensure the area is well-ventilated and free from sources of ignition or contamination. Avoid exposure to excessive heat or humidity to maintain the stability and efficacy of the compound.
    Application of Mitiglinide Calcium Dihydrate

    Applications of Mitiglinide Calcium Dihydrate in Industrial Manufacturing

    Mitiglinide Calcium Dihydrate plays a crucial role as a key active pharmaceutical ingredient in modern anti-diabetic drug production. Downstream manufacturers integrate this compound primarily in the field of oral hypoglycemic agent development for regulated global markets. The following sections detail practical industrial applications supported by real compliance frameworks, precise formulation guidelines, and finished product typologies.

    1. Oral Antidiabetic Tablet Manufacturing

    Our customers in the pharmaceutical sector utilize this ingredient to formulate fast-acting oral tablet drugs targeting postprandial hyperglycemia in Type 2 diabetes patients. Its unique calcium-based complex offers high solubility and bioavailability, allowing for efficient tablet compaction and precise dosage control during high-volume tableting operations. Pharmacies and healthcare facilities ultimately deliver these tablets to end users under branded prescriptions, with strict adherence to pharmaceutical quality and traceability demands.

    Industry compliance standards

    • European Pharmacopoeia (Ph. Eur., current edition)
    • United States Pharmacopeia (USP)
    • Good Manufacturing Practice (GMP, ICH Q7)
    • China National Medical Products Administration (NMPA) registration and DMF filing standards

    Typical usage ratio

    • 0.5 – 2.5 mg per tablet (typically 0.25%–1% of total tablet mass), adjusted according to target daily dosage strength and target release profile

    Downstream process integration

    • Enters direct granulation or wet granulation process post-blending with excipients such as microcrystalline cellulose, lactose, and magnesium stearate
    • QC sampling and uniformity testing follows API-excipient blending prior to tableting
    • Utilized in direct compression for ODT (orodispersible tablet) variants

    Final product types

    • Immediate-release antidiabetic tablets
    • Orally disintegrating antidiabetic tablets for rapid onset
    • Combination tablets blended with other hypoglycemic agents (e.g., metformin)

    2. Oral Antidiabetic Capsule Production

    Several generic drug manufacturers select this active compound as the essential component in capsule-based hypoglycemic drug products. The encapsulation process supports precise individual dosing and batch reproducibility, minimizing cross-contamination risk during multi-API manufacturing. Regulatory authorities require precise dosing and impurity limits for capsule applications, especially when supplying hospital or retail distribution chains in both developed and emerging markets.

    Industry compliance standards

    • Japanese Pharmacopoeia (JP)
    • Drug Master File (DMF) referencing and validation in FDA and PMDA submissions
    • ICH Q3A/B impurity profiles for oral solid dosage forms
    • Cross-contamination control per EU GMP Annex 15

    Typical usage ratio

    • 0.5 – 2.0 mg per capsule (generally 0.1%–0.5% by capsule fill weight), titrated to therapeutic regimen specified by downstream R&D

    Downstream process integration

    • Pre-mixed as micronized API with lactose or other approved diluents
    • Loaded into hard gelatin capsules via semi-automatic or fully-automated capsule filling lines
    • Subjected to in-process blending and content uniformity assays prior to final encapsulation and blister packing

    Final product types

    • Single-ingredient antidiabetic capsules
    • Fixed-dose combination capsule formulations with alpha-glucosidase inhibitors
    • Hospital supply generics for bulk procurement

    3. Fixed-dose Combination Drug Formulation

    Contract drug developers apply this material in multi-API combination products for advanced glycemic control, pairing it with other oral agents such as metformin or pioglitazone to address complex patient needs. These projects focus on reducing pill burden and improving treatment adherence in chronic care, and require highly monitored blending protocols and analytical verification for each API involved. Special attention is required to adjust the blend ratio for consistent dissolution and bioequivalence in the final combination product.

    Industry compliance standards

    • International Council for Harmonisation (ICH M9 Bioequivalence)
    • Chemical Drug Registration Standards (China FDA)
    • FDA's Guidance for Industry: Fixed-Combination Drugs
    • World Health Organization (WHO) Prequalification for Combination Medicines

    Typical usage ratio

    • 0.5 – 1.0 mg per dosage unit for this API, proportionally balanced with co-formulant APIs based on fixed combination prescription guideline

    Downstream process integration

    • Integrated into main powder blending stage, followed by wet or dry granulation
    • Granulation performed under segregated environment to ensure API homogeneity and mitigate interaction risk
    • Sequential compression for multi-layer tablet formats

    Final product types

    • Bilayer or multi-layer combination oral tablets
    • Fixed-dose polypharmacy caplets
    • Prescription antidiabetic kits for clinical dispensing

    4. Reference Standard Substance Supply for Analytical Laboratories

    Accredited pharmaceutical analysis labs and quality control centers secure high-purity samples of this compound as certified reference substances for analytical method development, system suitability testing, and batch release monitoring. The supplied material supports HPLC, LC-MS/MS, and impurity profiling studies to ensure downstream product compliance. Regulatory bodies audit traceability and certificate of analysis for each batch, so primary manufacturers provide multi-point QC verification to meet these downstream analytical requirements.

    Industry compliance standards

    • ISO/IEC 17025 laboratory accreditation
    • USP Reference Standard protocols
    • Good Laboratory Practice (GLP)
    • Regulatory requirements for analytical reference materials (FDA, EMA)

    Typical usage ratio

    • 2–10 mg per reference test, with scaling per laboratory SOP or analytical batch size; accuracy adjusted based on method validation requirements

    Downstream process integration

    • Directly weighed and dissolved in analytical-grade solvent for calibration and validation curves
    • Used in spiking experiments for impurity detection and recovery studies
    • Integrated in batch release protocols for finished drug product testing

    Final product types

    • Certified reference standard vials for internal QC labs
    • Third-party analytical kits for pharmaceutical batch release
    • In-house laboratory calibration solutions
    Free Quote

    Competitive Mitiglinide Calcium Dihydrate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.

    We will respond to you as soon as possible.

    Tel: +8615371019725

    Email: admin@sinochem-nanjing.com

    Get Free Quote of Sinochem Nanjing Corporation

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Mitiglinide Calcium Dihydrate: Practical Insights from the Manufacturer’s Floor

    Direct Experience with Mitiglinide Calcium Dihydrate Production

    Bringing a specialty compound like Mitiglinide Calcium Dihydrate to market involves more than formulas and laboratory work. Inside the plant, every batch depends on close control, active attention to the handling of sensitive intermediates, and the reliable performance of the team behind the chemistry. We see each kilogram leave the drying room after days of monitoring, knowing precisely where each raw material came from, and what critical variables shaped the final crystals. Years spent on synthesis, purification, and moisture control deliver a consistent product with more predictable tablet performance for our customers.

    Defining the Model: Precision and Consistency

    Our current model of Mitiglinide Calcium Dihydrate stems from process iterations that align with current pharmacopeia requirements. It presents as a fine, white crystalline powder with controlled particle size, low moisture content, and high purity—every batch measured by our own in-house HPLC, titration, and loss-on-drying methods. These controls matter in production. One year, a subtle shift in solvent grade led to detectably different flow and compactibility in the finished API. We caught it, traced it in the batch log, and overhauled supplier agreements. No distributor or trader will notice these shifts as quickly as a manufacturer at the source.

    Specifications Rooted in Practice

    Typical specifications call for assay values exceeding 99.0 percent, with residual solvents much lower than regulatory cut-offs. We manage microbial limits and heavy metal content with vigilance, not for marketing boasts, but because even a slight deviation drags down process reliability for our downstream partners. Whether weighed out by the gram or in hundred-kilogram drums, each lot comes with documentation traceable back to the exact blend and drying cycle. Several formulation partners have mentioned that direct sourcing from us means fewer interruptions, less out-of-spec reprocessing, and tighter integration with their own production schedules.

    Production Insights: Getting Beyond the Lab

    On the shop floor, it’s common to hear analysts debate the merits of crystallization temperatures or the merits of different filtration screens. Each adjustment changes the speed of drying, granule density, or how readily the API disperses in blending vessels at the customer’s site. We’ve tried rapid-dry techniques and slow evaporative approaches; right now, a controlled, stepwise dehydration after precipitation balances efficiency and uniform moisture. Technicians have shared that this particular hydration maintains easier handling during blending and less static cling for most tablet presses. Those seemingly small shifts add up, especially for automated dose filling.

    Usage Patterns Observed Among End-Users

    Mitiglinide Calcium Dihydrate finds its largest utility in oral anti-diabetic formulations, often aimed at rapid glycemic control. Because our team addresses potential cross-contamination in shared environments with strict segregation and rigorous cleaning validation, we see reduced concerns from our pharmaceutical clients. Larger buyers have expressed that direct-from-manufacturer packaging, with fewer warehouse hand-offs, preserves the original stability profiles longer, especially in humid coastal shipping environments. Some R&D teams have run stress studies under these conditions and shared that the compound as packaged here retains strength and flow much longer than batches acquired from intermediaries unable to guarantee chain of custody.

    Why Product Origin Matters: Manufacturer Versus Middleman

    In practice, chemicals that move through layers of distribution rarely show the same batch stability, packaging integrity, or traceability as those sourced straight from the maker. As manufacturers, we stand behind every drum; we track raw material lot numbers, and we can answer questions about minor changes in production logs that might explain a variance in dissolution times or moisture uptake. Clients who encounter inconsistent tablet machinability or dissolution with third-party batches often arrive at our door, asking for details from the process records to tune their own troubleshooting.

    Distinctives Versus Other Forms or Generics

    Mitiglinide comes in forms prepared by several routes—some supply only the base salt, others offer racemic blends or partly hydrated forms. Our Calcium Dihydrate model typically delivers enhanced chemical stability during transport, fewer caking incidents after long storage, and more predictable compressive behavior in tableting. Those aren’t just claims: our internal pilot plant runs compare the performance of finished tablets from different hydration states. We find the dihydrate yields consistently low friability, better uniformity in dose testing, and less tendency to take up environmental moisture during open-air dispensing. Distributors or re-packagers who attempt reprocessing by grinding or blending other forms often introduce static issues, increased dusting, and batch-to-batch variability—not always apparent until late in scale-up.

    Handling and Storage in Large-Scale Operations

    We have invested in climate-controlled bulk storage, sealed packaging solutions, and antistatic liners after encountering problems with powder agglomeration and static charge in earlier years. Walk into our warehouse, and you’ll see real-time temperature monitoring and humidity management with clear records on each lot. Those controls aren’t just for regulatory compliance; they directly reduce incidents of caked powder or inconsistent flow rates for packaging. One logistics manager from a key partner once remarked that switching to drums from our plant led to a double-digit reduction in downtime caused by unclogging feed hoppers. Simple upgrades like this flow directly from manufacturing experience.

    No Substitute for Batch-Level Detail

    Third-party resellers often market on price alone, but our customers keep coming back for answers and insight. A generic supplier may wipe out minor peaks on a chromatogram if it gets them a higher yield, but few commit to follow impurities and by-products through to late-stage stability testing the way we do. Recently, we adopted a new purity check at the request of a development client testing an innovative excipient. The insights our analytical chemists drew from side-by-side degradation studies led not just to a process tweak, but to improved shelf life and less risk of loss after long ocean freight transits. No distributor can offer that level of continuous technical feedback.

    Direct Feedback from Downstream Operations

    One of the privileges of manufacturing at the source involves hearing from process engineers, mill operators, and QC lab techs in the next link of the chain. Some have described real headaches with off-spec API purchased elsewhere—poor blending, clumpy feed, or delayed dissolution. By contrast, the batches moving out of our lot keep lines running, reduce manual intervention, and respond to minor punch pressure changes without dusting or sticking. Our technical support team partners directly with customers to interpret batch records or provide historical data on previous process changes, helping them optimize their own settings and reduce trial-and-error runs.

    Quality Assurance at Scale

    Inspection of every batch under stringent internal standards creates ongoing refinement in plant operations. There is no shortcut for active monitoring of process points like filtration, drying, and even packaging. Several equipment upgrades—such as nitrogen-flushed packing and automated weight checks—are a result of real incidents where the fidelity of the API in field conditions did not meet expectation. We learned quickly that the more thoroughly we understand our own critical quality attributes, the greater confidence our partners have in their finished medicines. For every deviation caught, there are lessons directly reinvested into better controls and more robust employee training.

    Value Beyond the Certificate of Analysis

    A document reports a moment in the product lifecycle, but our real investment shows through responsiveness to atypical observations and customer-specific requirements. Several strategic partners have leveraged detailed batch records to align their process operations with seasonal variance in shipping or extended warehouse storage. Because we build, store, and analyze on one campus, we can answer urgent queries about stability trials or validation lots in hours, not weeks. Data does not languish behind email firewalls. Our own R&D team frequently pilots unique customer processing environments, running parallel analyses under stress, heat, or prolonged storage so we can stand behind every shipment’s projected shelf life.

    Understanding End-Product Manufacturing Challenges

    Tableting runs that originate with Mitiglinide Calcium Dihydrate directly from our plant record lower rates of batch rejection and leach fewer fines into downstream dust collection. Many customers reported that switching to direct supply improved throughput by cutting loss during milling or granulation. Our in-house experts regularly adjust grind profiles to best suit end-user processing styles, from wet to dry granulation to direct compression. The tangible outcome for customers is fewer line stoppages, more consistent dose homogeneity, and a marked decrease in downstream process troubleshooting costs.

    Ongoing Innovation and Support

    Regular engagement with formulation scientists and process engineers drives continual improvement of our manufacturing process. The last three years saw several refinements requested by partners operating in high-humidity environments or seeking compliance with regionally unique regulatory demands. By tracking each suggestion and integrating real field test results, we developed a form of Mitiglinide Calcium Dihydrate that stores safely without silica-gel packs and withstands multi-climate shipping without clumping or loss of potency. That type of progress only happens when the manufacturer is involved from R&D bench work to commercial-scale delivery.

    Market Differences—Original Manufacturer Value

    Buyers face a chemical marketplace rich with options, but those choices narrow when reliability becomes the top priority. A tableting plant or packager with tight deadlines cannot afford disruptions from inconsistent API. Our long-term partners appreciate the smaller number of hands and warehouses their goods touch, minimizing chance for cross-contamination or confusion over chain of custody. Several procurement managers pointed to our willingness to customize lots—either by modifying packaging or adjusting particle parameters—as instrumental to smoother regulatory submissions and faster regulatory approval.

    Training and Knowledge Transfer at the Source

    Manufacturing at scale builds practical knowledge that supports our partners. New operators regularly rotate through all stages of production and testing so they can interpret chromatogram quirks or moisture anomalies without waiting for escalation. When a client flagged a sporadic issue with sticking tablets, we pulled archived humidity logs, compared powder X-ray diffraction results with past batches, and diagnosed a rare process blip that led to a procedural fix. Traders might swap suppliers to address such issues, but manufacturers like us invest in actionable technical answers.

    Risk Mitigation—The Manufacturer’s Role

    By controlling both process and packaging, we can anticipate and prevent issues before they reach tablet plants. This extends beyond obvious quality concerns to subtler variables—like rare earth contamination, trace solvent carryover, or contamination risk from shared transportation. Direct relationships between producer and user keep feedback loops short, eliminate guesswork over root causes, and provide full transparency for regulatory audits. Nearly all supply disruptions that made headlines across the sector started with vague accountability and poorly tracked inventory—issues a hands-on manufacturer easily avoids.

    Emphasizing Practical Support—Not Just Product Delivery

    A true manufacturer’s role does not end with dispatch. We track lot performance after delivery, field real-time reports from blending rooms and tableting lines, and maintain open channels for emergency support. Experiences across continents show that proactive advice—for example, on transitioning between old and new API lots—avoids unnecessary downtime and loss. Clients value not just the chemical itself, but the expertise and real-world support that come with it.

    Conclusion: Where Manufacturing Makes the Difference

    Mitiglinide Calcium Dihydrate may appear a standard chemical to outsiders, but close involvement in its daily production reveals a web of interdependent choices—raw material selection, process configuration, packaging solutions, and customer application feedback. Only by being present at every stage can a genuine manufacturer refine performance, trace every anomaly, and build the trust critical to pharmaceutical supply chains. Over years of listening and adapting, we’ve learned that success comes from close attention to detail, honest communication, and steadfast quality at every step. The end result: our partners receive a consistently superior product, tailored not by abstract spec sheets but by hands-on experience and shared commitment to continuous improvement.